Ever Supreme Bio Technology Co (ROCO:6712) EBIT : NT$526.1 Mil (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Ever Supreme Bio Technology Co EBIT?

Ever Supreme Bio Technology Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2025 was NT$102.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2025 was NT$526.1 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ever Supreme Bio Technology Co's annualized ROC % for the quarter that ended in Mar. 2025 was 19.44%. Ever Supreme Bio Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 596.20%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ever Supreme Bio Technology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 4.21%.

Ever Supreme Bio Technology Co EBIT Historical Data

The historical data trend for Ever Supreme Bio Technology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ever Supreme Bio Technology Co EBIT Chart

Ever Supreme Bio Technology Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

Get a 7-Day Free Trial

-136.62

397.44

264.61

623.22

460.87

Ever Supreme Bio Technology Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EBIT	Get a 7-Day Free Trial															37.73	131.53	38.65	252.96	102.95

Competitive Comparison of Ever Supreme Bio Technology Co's EBIT

For the Biotechnology subindustry, Ever Supreme Bio Technology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ever Supreme Bio Technology Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ever Supreme Bio Technology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ever Supreme Bio Technology Co's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Ever Supreme Bio Technology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$526.1 Mil.

Ever Supreme Bio Technology Co (ROCO:6712) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ever Supreme Bio Technology Co's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

	ROC % (Q: Mar. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2024 )	+	Invested Capital (Q: Mar. 2025 ))	/ count )
=	265.684 * ( 1 - 13.81% )	/	( (1108.997	+	1246.957)	/ 2 )
=	228.9930396	/	1177.977
=	19.44 %

where

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2136.096	-	132.938	-	( 938.175	-	max(0, 329.087	-	1223.248	+	938.175	))
=	1108.997

	Invested Capital		(Q: Mar. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2033.831	-	581.537	-	( 813.689	-	max(0, 816.34	-	1021.677	+	813.689	))
=	1246.957

Note: The Operating Income data used here is four times the quarterly (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Ever Supreme Bio Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2024		Q: Mar. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	411.784	/	( ( (48.583 + max(-49.864, 0))	+	(89.554 + max(-610.523, 0)) )	/	2 )
=	411.784	/	( ( 48.583	+	89.554 )	/	2 )
=	411.784	/	69.0685
=	596.20 %

where Working Capital is:

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(193.985	+	80.038	+	3.4920000000002)	-	(132.938	+	0	+	194.441)
=	-49.864

	Working Capital		(Q: Mar. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(102.956	+	82.905	+	9.3380000000001)	-	(581.537	+	0	+	224.185)
=	-610.523

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ever Supreme Bio Technology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2025 )
	=	526.085	/	12504.039
	=	4.21 %

Ever Supreme Bio Technology Co EBIT Related Terms

Thank you for viewing the detailed overview of Ever Supreme Bio Technology Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Ever Supreme Bio Technology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ever Supreme Bio Technology Co Ltd (ROCO:6712) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Keya Road, 4th Floor, No. 30, Daya District, Taichung, TWN

Website

https://www.ever-supreme.com.tw

Ever Supreme Bio Technology Co Ltd is a Taiwan-based company. The company is engaged in research, development, and manufacturing of new drugs related to human mesenchymal stem cells and immune cells. The company operates in two segments: Cell Preparation Business Unit and Other Operating Business. The company gained a majority of revenue from the cell preparation Business, which is engaged in the research, development, manufacture, and sales of various new drugs and cell preparations, and investments related to biotechnology and medical industry businesses.

Ever Supreme Bio Technology Co Headlines

No Headlines